newsfilter
← Latest News
GlobeNewswire·

Oyster Point Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

FDA Approved TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease on October 15, 2021 TYRVAYA Nasal Spray Net Product Revenue of $1.2 Million in Q4'21, plus $5.4 Million Recognized from Ji Xing P